Polio eradication in India: What is the future?

Indian Pediatrics

Volumn 40, Issue 5, 2003, Pages 455-462

  John, T Jacob ^a  

^a IAP Polio Eradication Committee   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; NUCLEOTIDE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; VIRUS VACCINE;

BIOLOGICAL WARFARE; CONFERENCE PAPER; COST CONTROL; DEVELOPING COUNTRY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; ECONOMICS; ENDEMIC DISEASE; EPIDEMIC; FLACCID PARALYSIS; GENE SEQUENCE; GENOTYPE; GOVERNMENT; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; INCIDENCE; INDIA; INFECTION CONTROL; INFECTION RISK; MEDICAL ETHICS; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; POLIOMYELITIS; POLIOMYELITIS VIRUS; PUBLIC HEALTH; VACCINATION; VACCINE PRODUCTION; VIRUS DETECTION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS MUTANT; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS TYPING; VIRUS VIRULENCE; WILD TYPE; WORLD HEALTH ORGANIZATION;

HUMANS; INDIA; POLIOMYELITIS; VACCINATION;

EID: 0037911330     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. John TJ. Can we eradicate poliomyelitis? In: Frontiers in Pediatrics. Eds Sachdev HPS, Choudhury P. New Delhi, Jaypee Brothers, 1996; pp 76-90.
2. John TJ. India's polio eradication efforts at cross roads. Indian Pediatr 1998; 35: 307-315.
3. Global eradication of poliomyelitis by the year 2000. In: Forty-first World Health Assembly, Geneva, 2-13 May 1988: Resolutions and Decisions Annexes (Resolution WHA 41.28). World Health Organization, Geneva, 1988.
4. John TJ. The final stages of the global eradication of polio. New Engl J Med 2000; 343: 806-807.
5. WHO Consultative Group. The relation between acute persisting spinal paralysis and poliomyelitis vaccine - results of a ten-year enquiry. Bull WHO. 1982, 60: 231-242.
6. Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. "Endgame" issues for the global polio eradication initiative. Clin Infect Dis 2002; 34: 72-77.
7. Kawamura N, Kohara M, Abe S, Komatsu T, Tago K, Arita M, et al. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol, 1989; 63: 1302-1309.
8. Skinner MA, Racaniello VR, Dunn G, Cooper J, Minor PD, Almond JW. New model for the secondary structure of the 5′ noncoding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure i's important for neurovirulence. J Mol Biol 1989; 207: 379-392.
9. Pollard SR, Dunn G, Cammack N, Minor PD, Almond JW. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol, 1989; 63: 4949-4951.
10. Evans DMA, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 polio vaccine genome. Nature 1985; 314: 548-550.
11. Minor, PD. The molecular biology of poliovaccines. J Gen Virol 1992; 73: 3065-3077.
12. Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizume S, Miyamura T, Prevalence of vaccine-derived polioviruses in the environment. J Gen Virol 2002; 83: 1107-1111.
13. John TJ. Vaccine-associated paralytic polio in India. Bull WHO 2002; 80: 917.
14. Kohler K, Banerjee K, Hlady WG, Andrus JK, Sutter RW. Vaccine-associated paralytic poliomyelitis in India during 1999: Decreased risk in spite of massive use of oral polio vaccine. Bull WHO. 2002;80:210-216.
15. Kew O, Morris-Glasgow, V Landarverde, M Berns, C Shaw, J Garib, et al. Outbreak of poliomyelitis in Hispanioloa associated with circulating type 1 vaccine-derived poliovirus. Science. 2002; 296: 356-359.
16. Bellmunt A, May G, Zell R, Pring A, Kerblom P, Vergagen W, et al. Evolution of poliovirus type 1 during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 1999; 265: 178-184.
17. Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. In: Progress in Polio Eradication: Vaccine Strategies for the End Game, Ed. Brown F. Development Biology, Baisel, Karger. 2001; pp 75-80.
18. John TJ. Immunization against polioviruses in developing countries. Rev Med Virol 1993; 3: 149-160.
19. Monto AS. The Epidemiology of Viral Infections. In: Topley and Wilson's Microbiology and Microbial Infections, 9th edn, Eds Mahey BWJ. Collier L Volume 1. London. Arnold, 1998; pp 235-257.
20. John TJ, Thacker N, Deshpande JM. Setback in polio eradication in India in 2002: Reasons and remedies. Indian Pediatr 2003; 40: 195-203.
21. John TJ. Anomalous observations on IPV and OPV vaccination. In: Progress in Polio Eradication: Vaccine Strategies for the End Game. Ed Brown F. Dev Biol Basel, Karger, 2001; pp 197-208.
22. Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: Generation of infectious virus in the absence of natural template. Science 2002; 297: 1016-1018.
23. Bhargava PM. Fighting the poliovirus. The Hindu, Chennai, December 12, 1999; p S4.